Glutamate plays a pivotal role in drug addiction, and the N-methyl- D -aspartate (NMDA) glutamate receptor subtype serves as a molecular target for several drugs of abuse. In this review, we will provide an overview of NMDA receptor structure and function, followed by a review of the mechanism of action, clinical efficacy, and side effect profile of NMDA receptor ligands that are currently in use or being explored for the treatment of drug addiction. These ligands include the NMDA receptor modulators memantine and acamprosate, as well as the partial NMDA agonist D -cycloserine. Data collected to date suggest that direct NMDA receptor modulators have relatively limited efficacy in the treatment of drug addiction, and that partial agonism of NMDA receptors may have some efficacy with regards to extinction learning during cue exposure therapy. However, the lack of consistency in results to date clearly indicates that additional studies are needed, as are studies examining novel ligands with indirect mechanisms for altering NMDA receptor function.
References
[1]
United Nations Office on Drugs and Crime. World Drug Report; United Nations Pulication: Vienna, Austria, 2009.
[2]
Results from the 2009 National Survey on Drug Use and Health, Volume 1. Summary of National Findings; U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services: Rockville, MD, USA, 2010.
[3]
Kalivas, P.W.; Volkow, N.D. New medications for drug addiction hiding in glutamatergic neuroplasticity. Mol. Psychiatry 2011, 16, 974–986, doi:10.1038/mp.2011.46.
[4]
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed.; American Psychiatric Press: Washington DC, USA, 2002.
Grant, B.F.; Dawson, D.A. Age of onset of drug use and its association with DSM-IV drug abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey. J. Subst. Abuse 1998, 10, 163–173, doi:10.1016/S0899-3289(99)80131-X.
[7]
Grant, B.F.; Dawson, D.A.; Stinson, F.S.; Chou, S.P.; Dufour, M.C.; Pickering, R.P. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991–1992 and 2001–2002. Drug Alcohol Depend. 2004, 74, 223–234, doi:10.1016/j.drugalcdep.2004.02.004.
[8]
Nestler, E.J. Molecular neurobiology of addiction. Am. J. Addict. 2001, 10, 201–217, doi:10.1080/105504901750532094.
[9]
Olive, M.F.; Cleva, R.M.; Kalivas, P.W.; Malcolm, R.J. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol. Biochem. Behav. 2012, 100, 801–810, doi:10.1016/j.pbb.2011.04.015.
[10]
Grant, J.E.; Potenza, M.N.; Weinstein, A.; Gorelick, D.A. Introduction to behavioral addictions. Am. J. Drug Alcohol Abuse 2010, 36, 233–241, doi:10.3109/00952990.2010.491884.
[11]
Sussman, S.; Lisha, N.; Griffiths, M. Prevalence of the addictions: a problem of the majority or the minority? Eval. Health Prof. 2011, 34, 3–56, doi:10.1177/0163278710380124.
[12]
Lee, H.W.; Choi, J.S.; Shin, Y.C.; Lee, J.Y.; Jung, H.Y.; Kwon, J.S. Impulsivity in internet addiction: a comparison with pathological gambling. Cyberpsychol. Behav. Soc. Netw 2012, 15, 373–377, doi:10.1089/cyber.2012.0063.
[13]
Gass, J.T.; Olive, M.F. Glutamatergic substrates of drug addiction and alcoholism. Biochem. Pharmacol. 2008, 75, 218–265, doi:10.1016/j.bcp.2007.06.039.
[14]
Nemirovsky, N.E.; Olive, M.F. Medications for the treatment of cocaine addiction: focus on glutamatergic compounds. In Cocaine Abuse: Pharmacology, Treatment and Relapse Prevention; Fang, X.C., Yue, L., Eds.; Nova Biomedical: Hauppauge, NY, USA, 2012; pp. 115–129.
[15]
Kalivas, P.W. The glutamate homeostasis hypothesis of addiction. Nat. Rev. Neurosci. 2009, 10, 561–572, doi:10.1038/nrn2515.
[16]
Myers, K.M.; Carlezon, W.A., Jr.; Davis, M. Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology 2011, 36, 274–293, doi:10.1038/npp.2010.88.
[17]
Seeburg, P.H. The molecular biology of mammalian glutamate receptor channels. Trends Neurosci. 1993, 16, 359–365, doi:10.1016/0166-2236(93)90093-2.
[18]
Nicoll, R.A.; Malenka, R.C. Expression mechanisms underlying NMDA receptor-dependent long-term potentiation. Ann. N. Y. Acad. Sci. 1999, 868, 515–525, doi:10.1111/j.1749-6632.1999.tb11320.x.
[19]
Tang, Y.P.; Shimizu, E.; Dube, G.R.; Rampon, C.; Kerchner, G.A.; Zhuo, M.; Liu, G.; Tsien, J.Z. Genetic enhancement of learning and memory in mice. Nature 1999, 401, 63–69, doi:10.1038/43432. 10485705
[20]
Lau, C.G.; Zukin, R.S. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat. Rev. Neurosci. 2007, 8, 413–426. 17514195
[21]
Albensi, B.C. The NMDA receptor/ion channel complex: A drug target for modulating synaptic plasticity and excitotoxicity. Curr. Pharm. Des. 2007, 13, 3185–3194, doi:10.2174/138161207782341321.
[22]
Hardingham, G.E.; Bading, H. The Yin and Yang of NMDA receptor signalling. Trends Neurosci. 2003, 26, 81–89, doi:10.1016/S0166-2236(02)00040-1.
[23]
Haberny, K.A.; Paule, M.G.; Scallet, A.C.; Sistare, F.D.; Lester, D.S.; Hanig, J.P.; Slikker, W.J. Ontogeny of the N-methyl-D-aspartate (NMDA) receptor system and susceptibility to neurotoxicity. Toxicol. Sci. 2002, 68, 9–17, doi:10.1093/toxsci/68.1.9.
[24]
Smith, P.F. Therapeutic N-methyl-D-aspartate receptor antagonists: will reality meet expectation? Curr. Opin. Investig. Drugs 2003, 4, 826–832. 14619404
[25]
Kew, J.N.C. Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential. Pharmacol. Ther. 2004, 104, 233–244, doi:10.1016/j.pharmthera.2004.08.010.
[26]
Chen, H.S.; Lipton, S.A. The chemical biology of clincially tolerated NMDA receptor antagonists. J. Neurochem. 2006, 97, 1611–1626, doi:10.1111/j.1471-4159.2006.03991.x.
[27]
Waxman, E.A.; Lynch, D.R. N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 2005, 11, 37–49, doi:10.1177/1073858404269012.
[28]
Dingledine, R.; Borges, K.; Bowie, D.; Traynelis, S.F. The glutamate receptor ion channels. Pharmacol. Rev. 1999, 51, 7–62. 10049997
[29]
Law, A.J.; Weickert, C.S.; Webster, M.J.; Herman, M.M.; Kleinman, J.E.; Harrison, P.J. Expression of NMDA receptor NR1, NR2A and NR2B subunit mRNAs during development of the human hippocampal formation. Eur. J. Neurosci. 2003, 18, 1197–1205, doi:10.1046/j.1460-9568.2003.02850.x. 12956718
[30]
Curran, H.V.; Monaghan, L. In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction 2001, 96, 749–760, doi:10.1046/j.1360-0443.2001.96574910.x.
[31]
Kotermanski, S.E.; Wood, J.T.; Johnson, J.W. Memantine binding to a superficial site on NMDA receptors contributes to partial trapping. J. Physiol. 2009, 587, 4589–4604, doi:10.1113/jphysiol.2009.176297.
[32]
Naassila, M.; Hammoumi, S.; Legrand, E.; Durbin, P.; Daoust, M. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol. Clin. Exp. Res. 1998, 22, 802–809, doi:10.1111/j.1530-0277.1998.tb03871.x.
[33]
Hood, W.F.; Compton, R.P.; Monahan, J.B. D-Cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci. Lett. 1989, 98, 91–95, doi:10.1016/0304-3940(89)90379-0.
[34]
Nestler, E.J.; Aghajanian, G.K. Molecular and cellular basis of addiction. Science 1997, 278, 58–63, doi:10.1126/science.278.5335.58.
[35]
Tzschentke, T.M.; Schmidt, W.J. N-methyl-D-aspartic acid-receptor antagonists block morphine-induced conditioned place preference in rats. Neurosci. Lett. 1995, 193, 37–40, doi:10.1016/0304-3940(95)11662-G.
[36]
Schenk, S.; Valadez, A.; Worley, C.M.; McNamara, C. Blockade of the acquisition of cocaine self-administration by the NMDA antagonist MK-801 (dizocilpine). Behav. Pharmacol. 1993, 4, 652–659. 11224234
[37]
Zdanys, K.; Tampi, R.R. A systematic review of off-label uses of memantine for psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 1362–1374, doi:10.1016/j.pnpbp.2008.01.008.
[38]
Robinson, D.M.; Keating, G.M. Memantine: A review of its use in alzheimerê？s disease. Drugs 2006, 66, 1515–1534, doi:10.2165/00003495-200666110-00015.
[39]
Semenova, S.; Danysz, W.; Bespalov, A. Low-affinity NMDA receptor channel blockers inhibit acquisition of intravenous morphine self-administration in naive mice. Eur. J. Pharmacol. 1999, 378, 1–8, doi:10.1016/S0014-2999(99)00431-8.
[40]
Hyytia, P.; Backstrom, P.; Liljequist, S. Site-specific NMDA receptor antagonists produce differential effects on cocaine self-administration in rats. Eur. J. Pharmacol. 1999, 378, 9–16, doi:10.1016/S0014-2999(99)00446-X.
[41]
Blokhina, E.A.; Kashkin, V.A.; Zvartau, E.E.; Danysz, W.; Bespalov, A.Y. Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. Eur. Neuropsychopharmacol. 2005, 15, 219–225, doi:10.1016/j.euroneuro.2004.07.005.
[42]
Popik, P.; Danysz, W. Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-D-aspartate receptor antagonist, memantine. J. Pharmacol. Exp. Ther. 1997, 280, 854–865. 9023300
[43]
Kotlinska, J.; Biala, G. Memantine and ACPC affect conditioned place preference induced by cocaine in rats. Pol. J. Pharmacol. 2000, 52, 179–185. 11055574
[44]
Popik, P.; Wrobel, M.; Rygula, R.; Bisaga, A.; Bespalov, A.Y. Effects of memantine, an NMDA receptor antagonist, on place preference conditioned with drug and nondrug reinforcers in mice. Behav. Pharmacol. 2003, 14, 237–244, doi:10.1097/00008877-200305000-00008.
[45]
Ribeiro Do Couto, B.; Aguilar, M.A.; Manzanedo, C.; Rodriguez-Arias, M.; Minarro, J. Effects of NMDA receptor antagonists (MK-801 and memantine) on the acquisition of morphine-induced conditioned place preference in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28, 1035–1043, doi:10.1016/j.pnpbp.2004.05.038.
[46]
Ribeiro Do Couto, B.; Aguilar, M.A.; Manzanedo, C.; Rodriguez-Arias, M.; Minarro, J. NMDA glutamate but not dopamine antagonists blocks drug-induced reinstatement of morphine place preference. Brain Res. Bull. 2005, 64, 493–503, doi:10.1016/j.brainresbull.2004.10.005.
[47]
Popik, P.; Wrobel, M.; Bisaga, A. Reinstatement of morphine-conditioned reward is blocked by memantine. Neuropsychopharmacology 2006, 31, 160–170. 15886718
[48]
Maldonado, C.; Rodriguez-Arias, M.; Castillo, A.; Aguilar, M.A.; Minarro, J. Effect of memantine and CNQX in the acquisition, expression and reinstatement of cocaine-induced conditioned place preference. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31, 932–939, doi:10.1016/j.pnpbp.2007.02.012. 17395352
[49]
Aguilar, M.A.; Manzanedo, C.; Ribiero Do Couto, B.; Rodriguez-Arias, M.; Minarro, J. Memantine blocks sensitization to the rewarding effects of morphine. Brain Res. 2009, 1288, 95–104, doi:10.1016/j.brainres.2009.06.100.
[50]
Bespalov, A.Y.; Zvartau, E.E.; Balster, R.L.; Beardsley, P.M. Effects of N-methyl-D-aspartate receptor antagonists on reinstatement of cocaine-seeking behavior by priming injections of cocaine or exposures to cocaine-associated cues in rats. Behav. Pharmacol. 2000, 11, 37–44, doi:10.1097/00008877-200002000-00004.
[51]
Bisaga, A.; Evans, S.M. Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology 2004, 16–24, doi:10.1007/s00213-003-1617-5.
[52]
Krupitsky, E.M.; Neznanova, O.; Masalov, D.; Burakov, A.M.; Didenko, T.; Romanova, T.; Tsoy, M.; Bespalov, A.; Slavina, T.; Grinenko, A.A.; et al. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Psychiatry 2007, 519–523.
[53]
Arias, A.J.; Feinn, R.; Covault, J.; Kranzler, H.R. Memantine for alcohol dependence: an open-label pilot study. Addict. Disord. Treat. 2007, 77–83.
[54]
Evans, S.M.; Levin, F.R.; Brooks, D.J.; Garawi, F. A pilot double-blind treatment trial of memantine for alcohol dependence. Alcohol. Clin. Exp. Res. 2007, 31, 775–782, doi:10.1111/j.1530-0277.2007.00360.x.
[55]
Hart, C.L.; Haney, M.; Foltin, R.W.; Fischman, M.W. Effects of the NMDA antagonist memantine on human methamphetamine discrimination. Psychopharmacology 2002, 164, 376–384, doi:10.1007/s00213-002-1225-9.
[56]
Kiefer, F.; Mann, K. Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy. Curr. Pharm. Des. 2010, 16, 2098–2102, doi:10.2174/138161210791516341.
[57]
Boismare, F.; Daoust, M.; Moore, N.; Saligaut, C.; Lhuintre, J.P.; Chretien, P.; Durlach, J. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol. Biochem. Behav. 1984, 21, 787–789, doi:10.1016/S0091-3057(84)80020-9.
[58]
Madamba, S.G.; Schweitzer, P.; Zieglg？nsberger, W.; Siggins, G.R. Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl-D-aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro. Alcohol. Clin. Exp. Res. 1996, 20, 651–658, doi:10.1111/j.1530-0277.1996.tb01667.x.
Zeise, M.L.; Kasparov, S.; Capogna, M.; Zieglg？nsberger, W. Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur. J. Pharmacol. 1993, 231, 47–52, doi:10.1016/0014-2999(93)90682-8.
[61]
Zeise, M.L.; Kasparow, S.; Capogna, M.; Zieglg？nsberger, W. Calcium diacetylhomotaurinate (CA-AOTA) decreases the action of excitatory amino acids in the rat neocortex in vitro. Prog. Clin. Biol. Res. 1990, 351, 237–242. 2236130
[62]
Rammes, G.; Mahal, B.; Putzke, J.; Parsons, C.; Spielmanns, P.; Pestel, E.; Spanagel, R.; Zieglgansberger, W.; Schadrack, J. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 2001, 40, 749–760, doi:10.1016/S0028-3908(01)00008-9.
[63]
Allgaier, C.; Franke, H.; Sobottka, H.; Scheibler, P. Acamprosate inhibits Ca2+ influx mediated by NMDA receptors and voltage-sensitive Ca2+ channels in cultured rat mesencephalic neurones. Naunyn-Schmied. Arch. Pharmacol. 2000, 362, 440–443, doi:10.1007/s002100000285.
[64]
Popp, R.L.; Lovinger, D.M. Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur. J. Pharmacol. 2000, 394, 221–231, doi:10.1016/S0014-2999(00)00195-3.
[65]
De Witte, P.; Littleton, J.; Parot, P.; Koob, G. Neuroprotective and abstinence-promoting effects of acamprosate : elucidating the mechanism of action. CNS Drugs 2005, 19, 517–537, doi:10.2165/00023210-200519060-00004.
[66]
Al Qatari, M.; Bouchenafa, O.; Littleton, J. Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol. Clin. Exp. Res. 1998, 22, 810–814, doi:10.1111/j.1530-0277.1998.tb03872.x.
[67]
Lhuintre, J.P.; Daoust, M.; Moore, N.D.; Chretien, P.; Saligaut, C.; Tran, G.; Bosimare, F.; Hillemand, B. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1985, 1, 1014–1016. 2859465
[68]
Mann, K.; Kiefer, F.; Spanagel, R.; Littleton, J. Acamprosate: recent findings and future research directions. Alcohol. Clin. Exp. Res. 2008, 32, 1105–1110, doi:10.1111/j.1530-0277.2008.00690.x.
[69]
Mcgeehan, A.J.; Olive, M.F. The anti-relapse compound acamprosate inhibits the development of a conditioned place preference to ethanol and cocaine but not morphine. Br. J. Pharmacol. 2003, 138, 9–12, doi:10.1038/sj.bjp.0705059.
[70]
Mcgeehan, A.J.; Olive, M.F. Attenuation of cocaine-induced reinstatement of cocaine conditioned place preference by acamprosate. Behav. Pharmacol. 2006, 17, 363–367, doi:10.1097/01.fbp.0000224384.01863.5f.
[71]
Bowers, M.S.; Chen, B.T.; Chou, J.K.; Osborne, M.P.H.; Gass, J.T.; See, R.E.; Bonci, A.; Janak, P.H.; Olive, M.F. Acamprosate attenuates cocaine and cue-induced reinstatement of cocaine-seeking behavior in rats. Psychopharmacology 2007, 195, 397–406, doi:10.1007/s00213-007-0904-y.
[72]
Spanagel, R.; Sillaber, I.; Zieglgansberger, W.; Corrigall, W.A.; Stewart, J.; Shaham, Y. Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress. Psychopharmacology 1998, 139, 391–401, doi:10.1007/s002130050730.
[73]
Mason, B.J.; Heyser, C.J. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. Expert Opin. Drug Saf. 2010, 177–188.
[74]
Kiefer, F.; Mann, K. Acamprosate: How, Where, and for Whom does it work? Mechanism of Action, Treatment Targets and Individualized Therapy. Current Pharmaceut. Des. 2010, 2098–2102, doi:10.2174/138161210791516341.
Mason, B.J.; Heyser, C.J. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. Expert Opin. Drug Saf. 2010, 9, 177–188, doi:10.1517/14740330903512943.
[77]
Kampman, K.M.; Dackis, C.; Pettinati, H.M.; Lynch, K.G.; Sparkman, T.; O'Brien, C.P. A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence. Addict. Behav. 2011, 36, 217–221, doi:10.1016/j.addbeh.2010.11.003.
[78]
Myers, K.M.; Carlezon, W.A.J. D-Cycloserine effects on extinction of conditioned responses to drug-related cues. Biol. Psychiatry 2012, 71, 947–955, doi:10.1016/j.biopsych.2012.02.030.
[79]
Sheinin, A.; Shavit, S.; Benveniste, M. Subunit specificity and mechanism of action of NMDA partial agonist D-Cycloserine. Neuropharmacology 2001, 41, 151–158, doi:10.1016/S0028-3908(01)00073-9.
[80]
Davis, M.; Ressler, K.; Rothbaum, B.O.; Richardson, R. Effects of D-Cycloserine on extinction: translation from preclinical to clinical work. Biol. Psychiatry 2006, 60, 369–375, doi:10.1016/j.biopsych.2006.03.084.
[81]
Botreau, F.; Paolone, G.; Stewart, J. d-Cycloserine facilitates extinction of a cocaine-induced conditioned place preference. Behav. Brain Res. 2006, 172, 173–178, doi:10.1016/j.bbr.2006.05.012.
[82]
Thanos, P.K.; Bermeo, C.; Wang, G.J.; Volkow, N.D. D-Cycloserine accelerates the extinction of cocaine-induced conditioned place preference in C57BL/c mice. Behav. Brain Res. 2009, 199, 345–349, doi:10.1016/j.bbr.2008.12.025.
Nic Dhonnchadha, B.A.; Szalay, J.J.; Achat-Mendes, C.; Platt, D.M.; Otto, M.W.; Spealman, R.D.; Kantak, K.M. D-Cycloserine deters reacquisition of cocaine self-administration by augmenting extinction learning. Neuropsychopharmacology 2010, 35, 357–367, doi:10.1038/npp.2009.139.
[85]
Torregrossa, M.M.; Sanchez, H.; Taylor, J.R. D-Cycloserine reduces the context specificity of Pavlovian extinction of cocaine cues through actions in the nucleus accumbens. J. Neurosci. 2010, 30, 10526–10533, doi:10.1523/JNEUROSCI.2523-10.2010.
Myers, K.M.; Davis, M. Mechanisms of fear extinction. Mol. Psychiatry 2007, 12, 120–150, doi:10.1038/sj.mp.4001939.
[88]
Childress, A.R.; McLellan, A.T.; O？Brien, C.P. Role of conditioning factors in the development of drug dependence. Psychiatr. Clin. North. Am. 1986, 9, 413–425. 3534813
[89]
Siegel, S.; Ramos, B.M. Applying laboratory research: drug anticipation and the treatment of drug addiction. Exp. Clin. Psychopharmacol. 2002, 10, 162–183, doi:10.1037/1064-1297.10.3.162.
[90]
Santa Ana, E.J.; Rounsaville, B.J.; Frankforter, T.L.; Nich, C.; Babuscio, T.; Poling, J.; Gonsai, K.; Hill, K.P.; Carroll, K.M. D-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: a pilot investigation. Drug Alcohol Depend. 2009, 104, 220–227, doi:10.1016/j.drugalcdep.2009.04.023.
[91]
Kamboj, S.K.; Joye, A.; Das, R.K.; Gibson, A.J.; Morgan, C.J.; Curran, H.V. Cue exposure and response prevention with heavy smokers: a laboratory-based randomised placebo-controlled trial examining the effects of D-Cycloserine on cue reactivity and attentional bias. Psychopharmacology 2012, 221, 273–284, doi:10.1007/s00213-011-2571-2.
[92]
Price, K.L.; McRae-Clark, A.L.; Saladin, M.E.; Maria, M.M.; DeSantis, S.M.; Back, S.E.; Brady, K.T. D-Cycloserine and cocaine cue reactivity: preliminary findings. Am. J. Drug Alcohol Abuse 2009, 35, 434–438, doi:10.3109/00952990903384332.
[93]
Price, K.L.; Baker, N.L.; McRae-Clark, A.L.; Saladin, M.E.; Desantis, S.M.; Santa Ana, E.J.; Brady, K.T. A randomized, placebo-controlled laboratory study of the effects of D-cycloserine on craving in cocaine-dependent individuals. Psychopharmacology 2012. in press.
[94]
Watson, B.J.; Wilson, S.; Griffin, L.; Kalk, N.J.; Taylor, L.G.; Munafo, M.R.; Lingford-Hughes, A.R.; Nutt, D.J. A pilot study of the effectiveness of D-Cycloserine during cue-exposure therapy in abstinent alcohol-dependent subjects. Psychopharmacology 2011, 216, 121–129, doi:10.1007/s00213-011-2199-2.
[95]
Hofmann, S.G.; Huweler, R.; MacKillop, J.; Kantak, K.M. Effects of D-Cycloserine on craving to alcohol cues in problem drinkers: preliminary findings. Am. J. Drug Alcohol Abuse 2012, 38, 101–107, doi:10.3109/00952990.2011.600396.
[96]
Groblewski, P.A.; Lattal, K.M.; Cunningham, C.L. Effects of D-Cycloserine on extinction and reconditioning of ethanol-seeking behavior in mice. Alcohol. Clin. Exp. Res. 2009, 33, 772–782, doi:10.1111/j.1530-0277.2009.00895.x.
[97]
Das, R.K.; Kamboj, S.K. Maintaining clinical relevance: considerations for the future of research into d-cycloserine and cue exposure therapy for addiction. Biol. Psychiatry 2012, 72, e29–30, doi:10.1016/j.biopsych.2012.05.030.
[98]
Gass, J.T.; Olive, M.F. Positive allosteric modulation of mGluR5 receptors facilitates extinction of a cocaine contextual memory. Biol. Psychiatry 2009, 65, 717–720, doi:10.1016/j.biopsych.2008.11.001.
Kufahl, P.R.; Hood, L.E.; Nemirovsky, N.E.; Barabas, P.; Halstengard, C.; Villa, A.; Moore, E.; Watterson, L.R.; Olive, M.F. Positive allosteric modulation of mGluR5 accelerates extinction learning but not relearning following methamphetamine self-administration. Front. Pharmacol. 2012, 3, 194. 23189054
[101]
Reichel, C.M.; Schwendt, M.; McGinty, J.F.; Olive, M.F.; See, R.E. Loss of object recognition memory produced by exteded access to methamphetamine self-administration is reversed by positive allosteric modulation of metabotropic glutamate receptor 5. Neuropsychopharmacology 2011, 36, 782–792, doi:10.1038/npp.2010.212.
Bird, M.K.; Lawrence, A.J. The promiscuous mGlu5 receptor - a range of partners for therapeutic possibilities? Trends Pharmacol. Sci. 2009, 30, 617–623, doi:10.1016/j.tips.2009.09.008.
[104]
Olive, M.F. Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction. Eur. J. Pharmacol. 2010, 639, 47–58, doi:10.1016/j.ejphar.2010.01.029.
[105]
Olive, M.F. Metabotropic glutamate receptor ligands as potential therapeutics for drug addiction. Curr. Drug Abuse Rev. 2009, 2, 83–98, doi:10.2174/1874473710902010083.
[106]
Carroll, F.I. Antagonists at metabotropic glutamate receptor subtype 5: structure activity relationships and therapeutic potential for addiction. Ann. NY Acad. Sci. 2008, 1141, 221–232, doi:10.1196/annals.1441.015.
